Pharmaceutical Articles

Beasley Allen has one of the largest and most technologically advanced Mass Torts practices in the country. The Mass Torts division represents numerous people in claims against companies that manufacture and/or market defective pharmaceuticals and/or medical devices. The resources devoted to this division allow the firm to competently and conscientiously handle any group of cases, no matter how large, along with particular catastrophic injury cases.

Our firm was recently involved in one of the greatest victories in Mass Torts history, against drug manufacturer Merck regarding the drug Vioxx. After more than five years of hard-fought and difficult litigation, Merck agreed to pay $4.85 billion, the largest pharmaceutical settlement in U.S. history, to resolve certain Vioxx-related claims involving plaintiffs who suffered a heart attack, including sudden cardiac death, or a stroke.

Hospira recalls heparin vials due to contamination with human hair

Posted: September 14, 2014

Hospira, Inc., is recalling one lot of its blood thinner Heparin after confirming that a piece of human hair was found floating in a sealed vial.

DEA introduces new drug take-back program to combat prescription drug abuse

Posted: September 13, 2014

A new Drug Enforcement Administration (DEA) rule aims to combat a growing epidemic of prescription drug addiction and abuse by authorizing pharmacies, hospitals, clinics, and others to serve as drop-off sites for unused prescription medications.

Researchers raise safety concerns about nanoparticles in sunscreens, baby power

Posted: September 12, 2014

Nanoparticles, or the tiny bits of particles produced when a mineral is broken down into smaller and smaller bits, have been present for years in consumer products from baby powder to sunscreens, however they may ultimately do more harm than

Study links commonly prescribed anti-anxiety, insomnia drugs to Alzheimer’s in elderly

Posted: September 11, 2014

Older people who used drugs known as benzodiazepines to relieve anxiety and help them sleep are more likely to develop Alzheimer’s disease, and those who use the drugs frequently and in higher doses are at even greater risk, a new

FDA to consider new single-dose anti-viral drug to fight seasonal flu

Posted: September 10, 2014

Peramivir, a new once-daily injectable drug, appears to be a safe and effective at alleviating most flu symptoms if taken within 48 hours of the onset of symptoms, according to Dr. Rich Whitley, the University of Alabama at Birmingham (UAB)

Judge orders mediation to resolve Fosamax lawsuits claiming femur fractures

Posted: September 9, 2014

A New Jersey federal judge told Merck & Co. that it is time to settle with plaintiffs in multidistrict litigation over femur fractures allegedly caused by its osteoporosis drug Fosamax. About 900 cases are still pending in the litigation, which

Federal jury hits Ethicon transvaginal mesh with $3.27 million verdict

Posted: September 9, 2014

Jo Huskey had no idea the turn her life would take after having a 30-minute procedure to implant Ethicon’s transvaginal mesh device in her body to correct urinary incontinence. Plaintiffs attorneys and their witnesses painted a picture for jurors of

Long-term pancreatic cancer risks with class of type 2 diabetes drugs still unknown

Posted: September 8, 2014

Drugs in a class of Type 2 diabetes medications known as DPP-4 inhibitors may not increase the short-term risk of pancreatic cancer, but the long-term risks are still unknown, according to a new study published in the journal Diabetes, Obesity

Johnson and Johnson knew in 2001 that its metal hips could poison patients

Posted: September 8, 2014

Johnson & Johnson knew as early as 2001 that its metal-on-metal DePuy Pinnacle hip implant could corrode inside the body and cause a type of blood poisoning known as metallosis, a plaintiff’s attorney said in opening statements in the first

FDA approves new type of cancer drug to treat advanced melanoma

Posted: September 8, 2014

A new type of cancer drug has been approved by the Food and Drug Administration (FDA) to treat advanced or inoperable melanoma that no longer responds to other drugs.